FSD Pharma Inc (CSE:HUGE) (NASDAQ:HUGE) CEO Raza Bokhari sat down with Proactive’s Christine Corrado at BIO CEO in New York. Bokhari says the Cobourg, Ontario-based company will initiate Phase 1 safety trials in patients for its lead drug candidate PP 101 micro-PEA in before the end of 1Q, aiming to treat symptoms related to fibromyalgia, a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.
FSD Pharma advancing its Phase 1 study in Australia
Quick facts: FSD Pharma
Price: 7.83 CAD
Market Cap: $63.21 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE